CancereGAPNCT04824859
A Geriatric Assessment Electronic Platform for Older Patients With Cancer (eGAP - Electronic Geriatric Assessment Platform)
A study testing Behavioral in people with Cancer, run by University of Rochester at 1 site in United States.
Trial summary
This project assesses the feasibility and usability of the geriatric assessment platform (electronic Geriatric Assessment Platform or eGAP in 50 older patients with cancer, their caregivers, and their oncology team. Using an iterative process, we will refine the eGAP based on input from stakeholders. Read more about this study
- Who is it for?
- Ages 60 years and older
- Conditions the study is for
- Cancer
- What is being tested?
- Behavioral
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 21 participants
- Where
- 1 siteUnited States
- Study dates
- 7 Dec 2021to 30 Apr 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥65 years
- Have a diagnosis of cancer
- Able to provide informed consent
- English-speaking (because the platform is currently in English)
- Age ≥21 years
- Selected by patient when asked if there is a "family member, partner, friend, or caregiver with whom you discuss or who can be helpful in health-related matters".
Show all 9Show fewer
- Able to provide informed consent
- English-speaking
- Oncologists, APPs, and nurses who care for the patient
Who cannot join
- N/A
Trial locations and contacts
1 site in 1 country.
About this study
This project assesses the feasibility and usability of the geriatric assessment platform (electronic Geriatric Assessment Platform or eGAP in 50 older patients with cancer, their caregivers, and their oncology team. Using an iterative process, we will refine the eGAP based on input from stakeholders.
Read the detailed description
A geriatric assessment is a multidisciplinary diagnostic process that can detect medical, psychosocial and functional problems not identified by routine evaluation. This can subsequently guide management of the identified problems. However, the time and resources required to incorporate a geriatric assessment into clinic visits remain the primary barriers for implementation. There is a need to increase the adoption of the geriatric assessment among general oncologists and to address the associated resource limitations. Our long-term goal is to utilize an electronic platform to facilitate completion of the geriatric assessment. This project assesses the feasibility and usability of the geriatric assessment platform (electronic Geriatric Assessment Platform or eGAP) in 50 older patients with cancer, their caregivers, and oncology providers. Using an iterative process, we will refine the eGAP based on input from stakeholders (patients, caregivers, oncologists, nurses, advanced practitioners)
- Conditions
- Cancer
- Being tested
- Behavioral
- Keywords
- Supportive Care, Cancer, mHealth, Geriatric
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BehavioralBehavioural
eGAP that allows patients to complete validated questionnaires, and these questionnaires will be summarized and recommendations provided to the treating team
| Study group | Role | What they receive |
|---|---|---|
| Experimental | Experimental | The eGAP consists of validated questionnaires that are used to assess health status of older adults with cancer. Based on patient responses, tailored recommendations will be provided. Receives: Behavioral: Behavioral |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility Retention Rate
Percentage of patients completing the assessments that are assigned to them on eGAP
Measured: 1 week
Secondary outcomes (3)
Recruitment rates
Percentage of patients who are approached and agree to enroll
Measured: 1 week
Self-Report Completion Time
Time spent on completing the self-reported assessments on the eGAP
Measured: 1 week
System Usability Scale
For patients, caregivers, and oncology providers: score on 10-item scale, ranging 0-100; higher score corresponds to greater usability
Measured: 1 week
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Apr 2021
- Study start7 Dec 2021
- Primary completion30 Apr 2023
- Study completion30 Apr 2023
Why it stopped: Technology issues
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by University of RochesterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Electronic geriatric assessment platform to collect data (e.g., functional status, comorbidity, psychological health) that may better reflect health status of older adults with cancer
- Masking
- None (open label)
- Enrolment
- 21 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Rochester
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Kah Poh Loh, University of Rochester
- Investigators
- Kah Poh Loh, Principal investigator, University of Rochester
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04824859
- Sponsor's protocol ID
- UCCS21026
- Acronym
- eGAP
- Status last verified
- Jul 2026
- First submitted
- 27 Mar 2021
- Last updated
- 7 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: A complete and final study protocol will be made publicly available through the University of Rochester Cancer Center Community Oncology Research Program Research Base Protocol and Data Sharing Committee. The full protocol and data will be made publicly available no later than the publication date of the study findings from the final dataset. The protocol will include a detailed description of the study population, hypotheses tested, measurement and assessment information, data definitions and codes, and the analysis plan utilized. We will be collecting identifying information. The final dataset will be stripped of identifiers prior to release for sharing. Published papers will be made available in portable document format.
Study at a glance
From the registry record, last updated by the sponsor on 7 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Geriatric Assessment Electronic Platform for Older Patients With Cancer (eGAP - Electronic Geriatric Assessment Platform)
- ClinicalTrials.gov ID
- NCT04824859
- Acronym / sponsor ID
- eGAP / UCCS21026
- Conditions
- Cancer
- Keywords
- Supportive Care, Cancer, mHealth, Geriatric
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Technology issues
- Enrolment
- 21 participants (actual)
- Lead sponsor
- University of RochesterUniversity, hospital or other
- Study start
- 7 Dec 2021 (actual)
- Primary completion
- 30 Apr 2023 (actual)
- Study completion
- 30 Apr 2023 (actual)
- First posted
- 1 Apr 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This project assesses the feasibility and usability of the geriatric assessment platform (electronic Geriatric Assessment Platform or eGAP in 50 older patients with cancer, their caregivers, and their oncology team. Using an iterative process, we will refine the eGAP based on input from stakeholders.
Detailed description
A geriatric assessment is a multidisciplinary diagnostic process that can detect medical, psychosocial and functional problems not identified by routine evaluation. This can subsequently guide management of the identified problems. However, the time and resources required to incorporate a geriatric assessment into clinic visits remain the primary barriers for implementation. There is a need to increase the adoption of the geriatric assessment among general oncologists and to address the associated resource limitations. Our long-term goal is to utilize an electronic platform to facilitate completion of the geriatric assessment. This project assesses the feasibility and usability of the geriatric assessment platform (electronic Geriatric Assessment Platform or eGAP) in 50 older patients with cancer, their caregivers, and oncology providers. Using an iterative process, we will refine the eGAP based on input from stakeholders (patients, caregivers, oncologists, nurses, advanced practitioners)
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Electronic geriatric assessment platform to collect data (e.g., functional status, comorbidity, psychological health) that may better reflect health status of older adults with cancer
| Arm | Type | Receives |
|---|---|---|
| Experimental | Experimental | Behavioral: BehavioralThe eGAP consists of validated questionnaires that are used to assess health status of older adults with cancer. Based on patient responses, tailored recommendations will be provided. |
Who may qualify
- Ages
- 60 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Age ≥65 years
- Have a diagnosis of cancer
- Able to provide informed consent
- English-speaking (because the platform is currently in English)
- Age ≥21 years
Key exclusion criteria (1 listed)
- N/A
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BehavioraleGAP that allows patients to complete validated questionnaires, and these questionnaires will be summarized and recommendations provided to the treating team | Behavioural | Experimental |
Primary outcome
Feasibility Retention Rate
Time frame: 1 week
Percentage of patients completing the assessments that are assigned to them on eGAP
3 secondary outcomes
Recruitment rates
Time frame: 1 week
Self-Report Completion Time
Time frame: 1 week
System Usability Scale
Time frame: 1 week
Results and safety
The study was stopped early (reason given: Technology issues). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jul 2026.
- Individual participant dataSharing planned: Yes. A complete and final study protocol will be made publicly available through the University of Rochester Cancer Center Community Oncology Research Program Research Base Protocol and Data Sharing Committee. The full protocol and data will be made publicly available no later than the publication date of the study findings from the final dataset. The protocol will include a detailed description of the study population, hypotheses tested, measurement and assessment information, data definitions and codes, and the analysis plan utilized. We will be collecting identifying information. The final dataset will be stripped of identifiers prior to release for sharing. Published papers will be made available in portable document format.
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kah Poh Loh principal investigator
University of Rochester
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Behavioral in people with Cancer, run by University of Rochester at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 7 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Technology issues). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility Retention Rate (time frame: 1 week). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jul 2026.